Tyra Biosciences has been downgraded to a Hold rating as it approaches critical phase 2 trial results for its drug dabogratinib, targeting FGFR3-altered IR-NMIBC patients. The company faces significant near-term risks and opportunities from multiple upcoming phase 2 readouts, including SURF302, SURF303, and BEACH301. Tyra's SNAP platform aims to improve efficacy and tolerability compared to existing pan-FGFR inhibitors. With $353.9 million in cash and a burn rate supporting operations into the second half of 2028, the company is financially prepared for these pivotal clinical data releases but must navigate clinical uncertainties.
Nvidia's stock rose over 5% last week following record Q2 earnings and an upward revision of its long-term revenue forecast, driven by strong demand for its Blackwell AI architecture. Finbold's AI Agent predicts the stock could rally further, reachin...
Diamondback Energy (FANG) reported strong quarterly earnings, beating EPS and revenue estimates, supported by robust free cash flow and significant debt repayments. The company is well-positioned to benefit from growing data center energy demand thro...
In 2026, major athletic apparel stocks Nike, Dick's Sporting Goods, and Lululemon have fallen sharply by 38%, 29%, and 52% respectively, while the broader retail sector and S&P 500 have risen. Nike's decline began after a disappointing guidance reset...
Binance founder Changpeng Zhao (CZ) expressed strong confidence that Bitcoin may overtake gold as the world's most important asset during the next major bull run. While gold currently holds a $15.9 trillion market valuation, far exceeding Bitcoin's $...
On September 6, Ripple shifted 1,363,614.85 RLUSD (about $1.36 million) from the XRP Ledger to Ethereum by burning the tokens on XRPL and minting the same amount on Ethereum seconds later. This cross-chain supply transfer rebalanced liquidity without...
